Updated Drug Development Scrip Report Responds to the Pharma Industry's Major Changes



    LONDON, Oct. 8 /CNW/ - Innovation in the pharma industry is not at a
standstill: it has changed direction. Where once small molecule research
provided the mainstay of companies' profits, biological drugs are now making
their presence felt. While the range of genomic sciences waits to make its
impact, biologicals are providing the current focus for novel discovery. Yet
biologicals do not behave like small molecules; the rules for their
development are different and they are often little understood.
    The 2007 update to the Scrip Report 'How Drugs are Developed' responds to
these changes. First published four years ago, and revised in 2005, the Report
aims to inform all those involved with pharmaceutical R&D how each of the
necessary disciplines fit together to take a new medicine from discovery to
market launch.
    Sections of the Report that previously focused on small molecules have
now been expanded to describe the corresponding processes for biologicals. To
increase its value even further, the 2007 update features two brand new
chapters. The first deals with project management: the fundamentals of
managing multidisciplinary teams and the ways in which the role is changing to
encompass external as well as internal interfaces. The second concerns the
growing interest in translational research; the ways in which laboratory
concepts can be converted into medical advances.
    The 234-page update retains all the Report's original sections, giving
readers a firm grounding in all the stages of drug development from drug
target hunting, lead generation and optimisation through to preclinical
research, clinical evaluation and post-marketing surveillance. It also gives a
step-by-step account of the various stages of preparing for drug development
and the processes involved in making regulatory submissions. The Report also
includes over 60 figures all of which serve to aid the reader's understanding
of the issues discussed.
    When the first edition of the Report was published in 2003, the impact of
sequencing the human genome was just being felt throughout the industry. Now,
in 2007, it is apparent that while providing promise for the future, there
will be no 'quick fix' for the industry and it must pursue an ever wider range
of opportunities to achieve its goals. The result is a networked industry
without historical parallel.
    Scrip Reports publishes an extensive range of pharmaceutical therapeutic
market reports, detailed analyses of the pharmaceutical market for specific
geographic areas, in-depth profiles of companies operating in the industry,
financial and statistical analyses, directories and other strategic reports on
the healthcare sector.
    Visit http://www.scripreports.com.




For further information:

For further information: Jenefer Trevena, Managing Editor, Scrip
Publishing, Tel: +44-(0)20-7017-6989, Email: jenefer.trevena@informa.com; To
purchase How Drugs are Developed 2007, contact: Andrew Maitland, Sales
Manager, Tel: +44-(0)20-7017-6859, Email: andrew.maitland@informa.com and
quote code JR20004P

Organization Profile

SCRIP REPORTS

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890